Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin

Atherosclerosis

Volumn 198, Issue 1, 2008, Pages 1-11

  Schwertner, Harvey A ^a   Vítek, Libor ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b Institute of Medical Biochemistry   (Czech Republic)

Author keywords

Cardiovascular disease risk; Coronary heart disease; Gilbert syndrome; Heme oxygenase; Oxidative stress; Serum bilirubin; UGT1A1*28 allele

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; BACTERIUM LIPOPOLYSACCHARIDE; BILIRUBIN; BILIVERDIN; BILIVERDIN REDUCTASE; CARBON MONOXIDE; CHALCONE DERIVATIVE; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DICLOFENAC; DOPAMINE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; HEME; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METALLOPORPHYRIN; NITRIC OXIDE; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHORBOL ESTER; PHYCOBILIN; PROBUCOL; PROSTAGLANDIN; PROTOPORPHYRIN; RAPAMYCIN; THIOL DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLELE; BILIRUBIN BINDING; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLEARANCE; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; GILBERT DISEASE; HEAT SHOCK; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RESTENOSIS; REVIEW; RISK FACTOR; ULTRAVIOLET RADIATION;

EID: 41049098411     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.01.001     Document Type: Review

References (75)

1. Vítek L., and Schwertner H.A. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 43 (2007) 1-57
2. Stocker R., and Perrella M.A. Heme oxygenase-1: a novel drug target for atherosclerotic diseases?. Circulation 114 (2006) 2178-2189
3. Morita T. Heme oxygenase and atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 1786-1795
4. Siow R.C.M., Sato H., and Mann G.E. Heme oxygenase-carbon monoxide signaling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide?. Cardiovasc Res 41 (1999) 385-394
5. Elbirt K.K., and Bonkovsky H.L. Heme oxygenase: Recent advances in understanding its regulation and role. Proc Assoc Am Physicians 111 (1999) 438-447
6. Bach F.H. Heme oxygenase-1: A therapeutic amplification funnel. FASEB J 19 (2005) 1216-1219
7. Abraham N.G., Asija A., Drummond G., and Peterson S. Heme oxygenase-1 gene therapy: Recent advances and therapeutic applications. Curr Gene Therapy 7 (2007) 89-108
8. Perrella M.A., and Yet S.F. Role of heme oxygenase-1 in cardiovascular function. Curr Pharm Des 9 (2003) 2479-2487
9. Scott J.R., Chin B.Y., Bilban M.H., and Otterbein L.E. Restoring HOmeostasis: is heme oxygenase-1 ready for the clinic?. Trends Pharmacol Sci 28 (2007) 200-205
10. Sedlak T.W., and Synder S.H. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113 (2004) 1776-1782
11. Stocker R., Yamamoto Y., McDonagh A., and Glazer A. Bilirubin is an antioxidant of possible physiological importance. Science 235 (1987) 1043-1046
12. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
13. Willis D., Moore A.R., Frederik R., and Willoughby D.A. Heme oxygenase: A novel target for the modulation of the inflammatory response. Nat Med 2 (1996) 87-90
14. Nakagami T., Toyomura K., Kinoshita T., and Morisawa S. A beneficial role of bile pigments as an endogenous tissue protector: Anticomplement effects of biliverdin and conjugated bilirubin. Biochim Biophys Acta 1158 (1993) 189-193
15. Neuzil J., and Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for α-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 269 (1994) 16712-16719
16. Wu T.W., Fung K.P., Wu J., Yang C.C., and Weisel R.D. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 51 (1996) 859-862
17. Schwertner H.A. Association of smoking and low serum bilirubin antioxidant concentrations. Atherosclerosis 136 (1998) 383-387
18. Vítek L., Jirsa Jr. M., Brodanová M., et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160 (2002) 449-456
19. Ishikawa K., Sugawara D., Goto J., et al. Heme oxygenase-1 inhibits atherogenesis in Watanabe heritable hyperlipidemic rabbits. Circulation 104 (2001) 1831-1836
20. Ishikawa K., Sugawara D., Wang X., et al. Heme oxygenase-1 inhibits atherosclerotic lesion formation in LDL-receptor knockout mice. Circ Res 88 (2001) 506-512
21. Ollinger R., Yamashita K., Bilban M., et al. Bilirubin and biliverdin treatment of atherosclerotic diseases. Cell Cycle 6 (2007) 39-43
22. Vítek L., Malíková I., Kvasnička J., Benáková H., and Novotný L. Relationship between serum bilirubin and markers of inflammation and oxidative stress (abstract). J Gastroenterol Hepatol 22 Suppl. 2 (2007) A235
23. Duckers H.J., Boehm M., True A.L., et al. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med 7 (2001) 693-698
24. Yet S.F., Tian R., Layne M.D., et al. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ Res 89 (2001) 168-173
25. Camejo G., Halberg C., Manschich-Lundin A., et al. Hemin binding and oxidation of lipoproteins in serum: Mechanism and effect on the interaction of LDL with human macrophages. J Lipid Res 39 (1998) 755-766
26. Tribble D., van den Berg J.M., Motchnik P.A., et al. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and α-tocopherol content. Proc Natl Acad Sci USA 91 (1994) 1183-1187
27. Tribble D.L., Rizzo M., Chait A., et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small dense low-density lipoproteins. Am J Med 110 (2001) 103-110
28. Benallaoua M., Francois M., Batteux F., et al. Pharmacologic induction of heme oxygenase 1 reduces inflammatory arthritis in mice. Arthritis Rheum 56 (2007) 2585-2594
29. Schwertner H.A., Jackson W.G., and Tolan G. Association of low serum concentrations of bilirubin with increased risk of coronary artery disease. Clin Chem 40 (1994) 18-23
30. Hopkins P.N., Wu L.L., Hunt S.C., et al. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16 (1996) 250-255
31. Breimer L.H., Spyropolous K.A., Winder A.F., Mikhailidis D.P., and Hamilton G. Is bilirubin protective against coronary artery disease?. Clin Chem 40 (1994) 1987-1988
32. Levinson S.S. Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Ann Clin Lab Sci 27 (1997) 185-192
33. Cerne D., Ledinski G., Kager G., et al. Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein B to apolipoprotein all ratio. Clin Chem Lab Med 38 (2000) 529-538
34. Hunt S.C., Kronenberg F., Eckfeldt J.H., et al. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis 154 (2001) 747-754
35. Ishizaka N., Ishizaka Y., Takahashi E., Yamakado M., and Hashimoto H. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke 32 (2001) 581-583
36. Krijgsman B., Papadakis J.A., Ganotakis E.S., Mikhailidis D.P., and Hamilton G. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol 21 (2002) 44-52
37. Kronenberg F., Coon H., Gutin A., et al. A genome scan for loci influencing anti-atherogenic serum bilirubin levels. Eur J Hum Genet 10 (2002) 539-546
38. Endler G., Hamwi A., Sunder-Plassmann R., et al. Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women?. Clin Chem 49 (2003) 1201-1204
39. Gullu H., Erdogan D., Tok D., et al. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Throm Vasc Biol 25 (2005) 2289-2294
40. Vítek L., Novotný L., Šperl M., Holaj R., and Spáčil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 21 (2006) 408-414
41. Yilmaz N., Cicek H.K., Celik A., and Davutoglu V. Diagnostic value of bilirubin concentrations compared with novel and traditional biomarkers in atherosclerosis with coronary artery disease. Saudi Med J 27 (2006) 1262-1264
42. Erdogan D., Gullu H., Yildirim E., et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184 (2006) 431-437
43. Yilmaz N., Cicek H.K., Celik A., et al. Diagnostic value of homocysteine, C-reactive protein and bilirubin for coronary artery disease. East Mediterr Health J 13 (2007) 522-535
44. Perlstein T.S., Pande R., Beckman J.A., and Creager M.A. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arteriocler Thromb Vasc Biol 28 (2008) 166-172
45. Perlstein T.S., Pande R., Beckman J.A., and Creager M.A. Serum total bilirubin level is inversely associated with likelihood of nonfatal stroke: National Health and Nutrition Examination Survey, 1999-2004 (abstract). Vasc Med 12 (2007) 146
46. Inoguchi T., Sasaki S., Kobayashi K., Takayanagi R., and Yamada T. Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. J Am Med Assoc 298 (2007) 1398-1400
47. Ganotakis E.S., Vrentzos G.E., Gazi I.F., et al. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo 21 (2007) 685-694
48. Breimer L.H., Wannamethee G., Ebrahim S., and Shaper A.G. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 41 (1995) 1504-1508
49. Hunt S.C., Wu L.L., Hopkins P.N., and Williams R.R. Evidence for a major gene elevating serum bilirubin concentration in Utah pedigrees. Arterioscler Thromb Vasc Biol 16 (1996) 912-917
50. Djousse L., Levy D., Cupples L.A., et al. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol 87 (2001) 1196-1200
51. Temme E.H., Zhang J., Schouten E.G., and Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12 (2001) 887-894
52. Djousse L., Rothman K.J., Cupples L.A., Levy D., and Ellison R.C. Effect of serum albumin and bilirubin on the risk of myocardial infarction (the Framingham Offspring Study). Am J Cardiol 91 (2003) 485-488
53. Troughton J.A., Woodside J.V., Young I.S., et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 14 (2007) 79-84
54. Novotný L., and Vítek L. Inverse relationship between serum bilirubin and atherosclerosis in men. A meta-analysis of published studies. Exp Biol Med 228 (2003) 568-571
55. Bosma P.J. Inherited disorders of bilirubin metabolism. J Hepatol 38 (2003) 101-107
56. Bosma P.J., van der Meer I.M., Bakker C.T., et al. UGT1A1*28 allele and coronary heart disease: The Rotterdam Study. Clin Chem 49 (2003) 1180-1181
57. Lin J.P., O'Donnell C.J., Schwaiger J.P., et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 114 (2006) 1476-1481
58. Schwertner H.A. Bilirubin concentration, UGT1A1*28 polymorphism, and coronary artery disease. Clin Chem 49 (2003) 1039-1040
59. Gajdos V., Petit F.M., Perret C., et al. Further evidence that the UGT1A1*28 allele is not associated with coronary artery heart disease: The ECTIM Study. Clin Chem 52 (2006) 2313-2314
60. Ko G.T., Chan J.C., Woo J., et al. Serum bilirubin and cardiovascular risk factors in a Chinese population. J Cardiovascular Risk 3 (1996) 459-463
61. Madhavan M., Wattingney W.A., Srinivasan S.R., and Berenson G.S. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis 131 (1997) 107-113
62. Papadakis J.A., Ganotakis E.S., Jagroop I.A., Mikhailidis D.P., and Winder A.F. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 12 (1999) 673-681
63. Kalousová M., Novotný L., Zima T., Braun M., and Vítek L. Decreased levels of advanced glycation end-product in patients with Gilbert syndrome. Cell Mol Biol 51 (2005) 387-392
64. Caliskan M., Erdogan D., Gullu H., Tok D., Bilgi M., and Muderrisoglu H. Low serum bilirubin concentrations are associated with impaired aortic elastic properties, but not impaired left ventricular diastolic function. Int J Clin Pract (2006) [Epub ahead of print]
65. Vítek L., Kráslová I., Muchová L., Novotný L., and Yamaguchi T. Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. J Gastroenterol Hepatol 22 (2007) 841-845
66. Schwertner H.A., and Fischer Jr. J.R. Comparison of various lipid, lipoprotein, and bilirubin combinations as risk factors for predicting coronary artery disease. Atherosclerosis 150 (2000) 381-387
67. Grosser N., Hemmerlee A., Berndt G., et al. The antioxidant defense proteinheme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 37 (2004) 2064-2071
68. Lee T.S., Chang C.C., Zhu Y.Y., and Shyy J.Y. Simvastatin induces heme oxygenase-1: A novel mechanism for vessel protection. Circulation 110 (2004) 1296-1302
69. Muchova L., Wong R.J., Hsu M., et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 85 (2007) 800-810
70. Brydun A., Watari Y., Yamamoto Y., et al. Reduced expression of heme oxygenase-1 in patients with coronary atherosclerosis. Hypertens Res 30 (2007) 341-348
71. McCarty M.F. Iatrogenic Gilbert syndrome-A strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 69 (2007) 1367-1370
72. Schindhelm R.K., Diamant M., Dekker J.M., et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22 (2006) 437-443
73. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 191 (2007) 391-396
74. Ioannou G.N., Weiss N.S., Boyko E.J., Mozaffarian D., and Lee S.P. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43 (2006) 1145-1151
75. Wei M., Schwertner H.A., Zeng Q., and Blair S.N. Fasting serum bilirubin concentrations and the risk of subsequent coronary heart disease death in men (abstract). Hepatology 32 (2000) 314A